Triapine
Phase 2Small molecule
Triapine is a small molecule that works as a Ribonucleotide Reductase Inhibitor.[2] It is being investigated across 3 indications, with its most advanced program in Phase 2.[1]
Triapine is one of 11 small molecule programs targeting Uterine Cancer. It is currently in Phase 2.
3
Indications
34
Total Trials
7
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Uterine Cancer
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Femara
NovartisApproved
Taxol
TevaPhase 3
Gemzar
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 2
Adavosertib
AstraZenecaPhase 2
Paraplatin
AAvyxa
Phase 2
Triapine
VVion Pharmaceuticals
Phase 2
RP-6306
DDebiopharm International SA
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer3 trials
Non-Small Cell Lung Cancer3 trials
Advanced Cancer2 trials
Patients With Solid Tumors1 trial
24 more indications
Cancer of the Pancreas1 trial
Advanced Hematologic Malignancies1 trial
Breast Cancer1 trial
Metastatic Cancer1 trial
Myelodysplastic Syndrome1 trial
Radiation Therapy1 trial
Advanced or Metastatic Solid Tumors1 trial
Renal Cell Carcinoma1 trial
Uterine Cancer1 trial
Adenocarcinoma1 trial
Unresectable Solid Tumor1 trial
Cervical Cancer1 trial
Primary Peritoneal Cancer1 trial
Advanced Cervical Adenocarcinoma1 trial
Advanced Vaginal Adenocarcinoma1 trial
Astrocytoma, IDH-Mutant, Grade 21 trial
Metastatic Digestive System Neuroendocrine Neoplasm1 trial
Recurrent Glioblastoma IDH Wildtype1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Triapine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Ribonucleotide Reductase Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- VVion Pharmaceuticals